New drug combo before stem cell transplant for high-risk leukemia or MDS
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of a new drug (SHR2554) with another medication (azacitidine) and a conditioning regimen before a stem cell transplant. It aims to improve outcomes for high-risk or relapsed leukemia and MDS patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 60 years old.
- You must have acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or a myelodysplastic syndrome (MDS) that is high-risk, relapsed/refractory, or has certain high-risk features.
- You must not have had a stem cell transplant before.
- You must not have active leukemia in the brain or spinal fluid (central nervous system leukemia).
- You must not have been previously treated with an EZH2 inhibitor (a type of targeted therapy).
- You must have adequate heart, lung, liver, and kidney function, and be generally well enough (performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.